Why MASH Matters: The Next Steps in Liver Disease Innovation with 89bio’s Rohan Palekar

In this episode of the Xtalks Life Science Podcast, Editor-in-Chief Vera Kovacevic speaks with Rohan Palekar, CEO of 89bio, about one of the fastest-growing public health challenges: metabolic dysfunction-associated steatohepatitis (MASH), also known as fatty liver disease. MASH is projected to affect more than 27 million Americans by 2030, yet it remains a largely “silent” epidemic. Palekar discusses what sets MASH apart from other liver diseases, the urgent need for therapies that can rapidly reverse fibrosis in advanced patients and the unique challenges drug developers face in addressing this condition. The conversation explores the drivers behind the sharp rise in MASH prevalence and what may define the future therapeutic landscape. Palekar also reflects on his leadership journey at 89bio and shares what’s next for the company as it advances new therapies for MASH and beyond. Tune in to learn how 89bio is working to transform care for patients living with MASH and why this disease represents one of the most important — yet underrecognized — health challenges of the decade. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured